October 25–26, 2016
The specific objectives of the workshop include:
- Sharing of experiences using stem cell-derived cardiomyocytes (SC-CMs) including hiPSC-CMs and embryonic stem cells-derived cardiomyocytes (hESC-CMs) for the testing of electrophysiological effects and the assessment of resultant proarrhythmic risk or other drug-induced safety risks (e.g., contractility or calcium homeostasis).
- Define the cell characteristics needed for use in a given assay system.
- Discuss in vitro assay methods and markers needed to standardize the defined phenotype of hiPSC-CM and ensure quality.
- Discuss the role of electrophysiological studies of cardiac myocytes to predict the proarrhythmic potential of drugs.
- Identify advanced uses of hiPSC-CM that can be used to identify potential cardiovascular risk.
SPS Members may attend this meeting at a discount since the Society is a Scientific Liaison Coalition (SLC) Member.
More information can be found on the workshop website.